for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford BioMedica plc

OXB.L

Latest Trade

555.00GBp

Change

2.00(+0.36%)

Volume

17,087

Today's Range

550.00

 - 

558.00

52 Week Range

461.50

 - 

794.88

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

Oxford BioMedica Posts H1 Revenue Down 9%

Sept 4 (Reuters) - Oxford BioMedica PLC <OXB.L>::H1 REVENUE FELL 9 PERCENT TO 32.1 MILLION STG.OXFORD BIOMEDICA INTERIM RESULTS.HY REVENUES WERE £32.1 MILLION, A DECREASE OF 9%.EXPECTS, AS PREVIOUSLY OBSERVED, A STRONGER SECOND HALF OF YEAR.CAPEX SPEND IN SECOND HALF OF 2019 WILL CONTINUE AT A HIGHER RATE THAN IN 2018.HY OPERATING LOSS £6.1 MILLION.

Oxford Biomedica Says Novo Holdings Agreed To Invest Up To £53.5 Mln In Group

May 28 (Reuters) - Novo Nordisk A/S <NOVOb.CO>::OXFORD BIOMEDICA - NOVO HOLDINGS A/S AGREED TO INVEST UP TO £53.5 MILLION IN GROUP.OXFORD BIOMEDICA - NOVO HOLDINGS' INVESTMENT IN RETURN FOR NEW ORDINARY SHARES REPRESENTING UP TO 10.1% OF OUTSTANDING SHARES AFTER CAPITAL INCREASE.OXFORD BIOMEDICA PLC - PROCEEDS FROM DEAL WILL BE USED TO REPAY EXISTING DEBT FACILITY WITH OAKTREE CAPITAL MANAGEMENT IN FULL.OXFORD BIOMEDICA - PROCEEDS FROM DEAL WILL ALSO BE USED TO TO FURTHER DEVELOP LENTIVECTOR PLATFORM AND PROPRIETARY PRODUCT PORTFOLIO.

Oxford Biomedica Says Japanese Approval Of Kymriah

March 26 (Reuters) - Oxford BioMedica PLC <OXB.L>::JAPANESE APPROVAL OF KYMRIAH® (TISAGENLECLEUCEL).NOTES AN ANNOUNCEMENT BY NOVARTIS THAT JAPAN'S MINISTRY OF HEALTH, LABOR AND WELFARE (MHLW) HAS APPROVED KYMRIAH.

Oxford Biomedica's FY Gross Income Increased By 72 Pct

March 14 (Reuters) - Oxford BioMedica PLC <OXB.L>::PRELIMINARY RESULTS.FY GROSS INCOME INCREASED BY 72% TO £67.9 MILLION (2017: £39.4 MILLION).FY REVENUE INCREASED BY 78% TO £66.8 MILLION (2017: £37.6 MILLION).FY ADJUSTED OPERATING EXPENSES INCREASED BY 38% TO £31.7 MILLION (2017: £22.9 MILLION).FY OPERATING EBITDA OF £13.4 MILLION (2017: OPERATING EBITDA LOSS OF £1.9 MILLION).YEAR-END INVENTORIES INCREASED DUE ONGOING BIOPROCESSING COMMITMENTS ACROSS 2018 AND INTO 2019 FOR BREXIT PLANNING.GROUP HAS ASSESSED FUTURE IMPACT OF BREXIT ON ITS OPERATIONS TO BE MINOR.

Oxford Biomedica Enters Into Collaboration With Microsoft Research

March 12 (Reuters) - Microsoft Corp <MSFT.O>::ENTERED INTO A RESEARCH AND DEVELOPMENT COLLABORATION WITH MICROSOFT RESEARCH.COLLABORATION TO IMPROVE YIELD AND QUALITY OF NEXT GENERATION GENE THERAPY VECTORS USING CLOUD AND MACHINE LEARNING.

Oxford Biomedica Provides An Update On Programmes Outlicensed To Sanofi

Feb 7 (Reuters) - Oxford BioMedica PLC <OXB.L>::UPDATE ON PROGRAMMES OUTLICENSED TO SANOFI.SANOFI HAS CONFIRMED THAT IT WILL CONTINUE WITH ITS ONGOING PHASE I/II PROOF-OF-CONCEPT STUDY WITH SAR422459.SANOFI INTENDS TO SEEK A NEW PARTNER FOR OXB'S OUTLICENSED OPHTHALMOLOGY GENE THERAPIES.SANOFI WILL NOT CONTINUE TO DEVELOP SAR421869.SANOFI IS CURRENTLY IN DISCUSSIONS WITH POTENTIAL EXTERNAL PARTNERS TO CONTINUE FURTHER DEVELOPMENT OF BOTH OF THESE PROGRAMMES.

Oxford Biomedica Says HY Gross Income Growth Of 118 Pct To 36 Mln Stg

Sept 13 (Reuters) - Oxford BioMedica PLC <OXB.L>::HY GROSS INCOME GROWTH OF 118 PERCENT TO £36.0 MILLION.HY LICENCE INCOME OF £18.3 MILLION RECOGNISED SEGMENTED BY PRODUCT (£10.2 MILLION) AND PLATFORM (£8.1 MILLION).

Oxford Biomedica Says European Commission Approved Novartis Car-T Cell Therapy

Aug 28 (Reuters) - Oxford BioMedica PLC <OXB.L>::NOTES THAT EUROPEAN COMMISSION (EC) HAS APPROVED NOVARTIS CAR-T CELL THERAPY, KYMRIAH.

Patrick Machado Says Axovant Sciences Agreed To Sell To Roivant 14.3 Mln Shares

June 7 (Reuters) - Patrick Machado::PATRICK MACHADO SAYS ON JUNE 5, ROIVANT ENTERED SHARE PURCHASE AGREEMENT - SEC FILING.PATRICK MACHADO SAYS AXOVANT SCIENCES AGREED TO ISSUE, SELL TO ROIVANT 14.3 MILLION SHARES AT $1.75/ SHARE IN A PRIVATE PLACEMENT.PATRICK MACHADO SAYS ROIVANT PROVIDED FINANCING WITH AXOVANT'S ENTRY TO LICENSE AGREEMENT WITH OXFORD BIOMEDICA.PATRICK MACHADO - ROIVANT REMAINS DIRECT OWNER OF 89.3 MILLION SHARES OF AXOVANT, INCLUDING 75 MILLION SHARES BENEFICIALLY OWNED BEFORE AXOVANT’S IPO.PATRICK MACHADO SAYS SHARES DISPOSITIVE POWER OVER ROIVANT’S 89.3 MILLION SHARES OF AXOVANT WITH OTHER INDEPENDENT DIRECTOR OF ROIVANT CURRENTLY SERVING.

Oxford Biomedica Announces ‍Proposed Placing To Raise About 20.5 Mln STG

March 9 (Reuters) - Oxford Biomedica Plc <OXB.L>::OXFORD BIOMEDICA PLC - ‍PROPOSED PLACING TO RAISE APPROXIMATELY £20.5 MILLION​.OXFORD BIOMEDICA - TO RAISE ABOUT £20.5 MILLION BY WAY OF CONDITIONAL PLACING OF UP TO 174.3 MILLION NEW SHARES AT A PRICE OF 11.75 PENCE PER PLACING SHARE​.OXFORD BIOMEDICA PLC - PLACING ‍TO FUND EXPANSION OF ITS BIOPROCESSING FACILITIES​.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up